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Membranous Nephropathy
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Abstract
Membranous nephropathy (MN) is a glomerular disease that is the lead-
ing cause of nephrotic syndrome in non-diabetic Caucasian adults. MN is most 
often primary (idiopathic) and the remaining is secondary to systemic disease or 
exposure to infection or drugs. The majority of patients with MN have circulating 
antibodies to the podocyte antigens phospholipase A2 receptor (PLA2R) (70%) and 
thrombospondin type-1 domain-containing 7A (THSD7A) (3–5%). Immunologic 
remission (depletion of PLA2R antibodies) often precedes and may predict clinical 
remission. Untreated, about one-third of patients undergo spontaneous remis-
sion, one-third have persistent proteinuria but maintain kidney function and 
the remaining one-third will develop end stage kidney failure. All patients with 
idiopathic MN should be treated with conservative care from the time of diagnosis 
to minimise proteinuria. Immunosuppressive therapy is traditionally reserved for 
patients who have persistent nephrotic-range proteinuria despite conservative care. 
Immunosuppressive agents for primary MN include combination of corticosteroids/
alkylating agent or calcineurin inhibitors and rituximab. This chapter will review 
the epidemiology, diagnosis and treatment of MN, particularly focusing on idio-
pathic MN.
Keywords: membranous nephropathy, PLA2R antibody, cytotoxic agents, 
calcineurin inhibitor, rituximab
1. Introduction
Idiopathic membranous nephropathy (MN) remains the leading cause of 
nephrotic syndrome in Caucasian adults and one of the most common primary 
glomerular diseases to progress to end-stage kidney disease (ESKD) [1, 2]. Secondary 
MN is associated with autoimmune diseases (e.g., systemic lupus erythematosus), 
infections (e.g., hepatitis B and C), medications (e.g., nonsteroidal anti-inflammatory 
drugs, d-penicillamine, gold), and neoplasias [3]. As idiopathic and secondary forms 
have similar clinical presentations, the designation of idiopathic is made only after 
ruling out secondary causes by a careful history, physical examination, and laboratory 
evaluation. This chapter will primarily focus on idiopathic MN.
2. Epidemiology
MN accounts for 20–30% of cases of nephrotic syndrome in Caucasian adults 
[4, 5]. Although the disease affects patients of all ages, all ethnicities and both 
sexes, it is more common in white men [4, 6]. MN has a peak incidence during 
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the fourth and fifth decades of life, and is relatively uncommon in patients aged 
under 20 years [4, 6]. The incidence of ESKD is about 35% at 10 years [7].
3. Pathogenesis
In the past decade, the understanding of the pathogenesis of idiopathic MN has 
significantly improved. In 2009, phospholipase A2 receptor (PLA2R) was identified as 
the major antigen responsible for autoantibody binding in idiopathic MN [8]. PLA2R 
is a transmembrane receptor that is highly expressed in glomerular podocytes and 
anti-PLA2R (typically of IgG4 subtype) was initially identified in 70% of patients 
with idiopathic MN [8]. Subsequent studies from various cohorts have shown that 
PLA2R antibodies are positive in 50–80% of patients with idiopathic MN [4, 6, 9–12]. 
PLA2R antibodies are uncommon in patients with MN associated with malignancies 
[13, 14]. PLA2R antibody has been reported in hepatitis-B associated membranous 
nephropathy [15] and also in hepatitis-C associated membranous nephropathy [14]. 
In genetic studies, there was association with HLA-DQA1 risk alleles [16, 17] and 
PLA2R1 alleles [16]. Furthermore, the presence of HLA DQA1*05:01 and DQB1*02:01 
alleles are associated with higher PLA2R antibody levels [18].
PLA2R is a 180-kDa membrane receptor with a large extracellular region 
comprising 10 distinct globular domains, including a cysteine-rich domain, a 
fibronectin type II domain, and eight distinct C-type lectin domains (CTLD1–8) 
[19]. Each domain is separated by a small linker sequence of <10 amino acids. CysR 
is the immunodominant epitope for PLA2R [20]. Epitope spreading refers to the 
development of immune responses to endogenous epitopes secondary to the release 
of self-antigens during a chronic autoimmune or inflammatory response. In MN, 
epitope-spreading starts with the cysteine-rich domain then extends to CTLD1, 
CTLD7 or other nearby regions. This results in an augmented immune response 
through heightened antibody diversity. In a study of 69 patients with MN from five 
French centres, Seitz-Polski et al. demonstrated that higher anti-PLA2R antibody 
titres and serum reactivity to CTLD1 and/or CTLD7 in addition to the cysteine-rich 
domain were associated with a higher rate of kidney failure [21].
A second IgG4 auto-antibody against thrombospondin type-1 domain-containing 
7A (THSD7A) was identified in a smaller number of patients with MN. THSD7A, like 
PLA2R, is also a protein highly expressed in podocytes and was identified in European 
and North American patients with anti-PLA2R-negative idiopathic MN but not in 
healthy controls or patients with other glomerular diseases [22]. It occurred in 2–5% of 
all patients with idiopathic membranous nephropathy, which corresponded to 8–14% 
of patients who were seronegative for anti-PLA2R antibodies. A recent meta-analysis 
of 10 studies involving 4121 patients showed that the prevalence of THSD7A was low 
at 3% (95% CI 2–4%) of all patients with idiopathic MN, which corresponded to 
10% (95% CI 6–15%) of anti-PLA2R antibody negative patients [23]. However, this 
meta-analysis was limited by a limited number of studies and small sample size. This 
meta-analysis also showed that cancer may be more common in patients with THSD7A 
antibodies and the incidence varied from 6 to 25%. Further studies to elucidate the role 
of THSD7A as a marker of prognosis and response to therapy are required.
Antibodies against both PLA2R and THSD7A can coexist but only in 1% of cases [24].
4. Pathology
Despite the availability of anti-PLA2R antibody, kidney biopsy remains the 
standard of care in diagnosing MN. In early MN, glomeruli may appear normal by 
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light microscopy. However, with time, the glomerular basement membrane thickens 
and there is formation of subepithelial “spikes” of basement membrane on the 
outer surface of the capillary wall. These “spikes” are more apparent with silver 
methenamine staining (Figure 1). Immunofluorescence microscopy reveals dif-
fuse, uniform, finely granular deposits of IgG4 along the outer surfaces of capillary 
walls (Figure 2). Complement components, including C3, C4d and C5b-9, are also 
Figure 1. 
Glomerulus showing thickening of glomerular basement membrane and subepithelial “spikes” (see arrowhead) 
in MN (silver-methamine stain).
Figure 2. 
Immunofluorescence showing diffuse fine granular distribution pattern of immunoglobulin G (IgG) along the 
glomerular basement membrane.
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commonly present, but not C1q. The antigens, PLA2R and THSD7A, co-localise 
with IgG4 in most patients with idiopathic MN.
Electron microscopy shows diffuse subepithelial electron-dense deposits and 
also glomerular basement membrane thickening (Figure 3). The deposits are 
gradually incorporated within new glomerular basement membrane and become 
more electron-lucent as they are resorbed before eventually disappearing in patients 
following the development of complete remission (CR).
5. Clinical manifestations
At presentation, 60–70% of patients will have nephrotic syndrome [25, 26]. The 
remaining one-third is presented with sub nephrotic-range proteinuria (<3.5 g/day) 
[27]. Microscopic hematuria also occurs in approximately one-third of patients; 
however, macroscopic hematuria is unusual and should prompt consideration of 
alternative diagnoses [28]. Hypertension and moderate-to-severe kidney failure 
occur in a minority of patients and tend to occur more commonly in older individu-
als [29]. Dyslipidaemia is common and venous thromboembolism has been reported 
to occur in approximately 7% [30].
6. Natural history
MN is a chronic disease, with spontaneous remission and relapses. There is 
great variability in the rate of disease progression, and the natural course is dif-
ficult to assess [31–33]. Spontaneous remissions are said to occur in up to 30% of 
cases. The proportion of patients going into spontaneous remission is much lower 
when patients have higher grades of proteinuria or high anti-PLA2R antibody titre 
(>85 RU/mL) at presentation [34]. The remaining two-thirds of patients who do 
not undergo spontaneous remission either have persistent proteinuria with stable 
kidney function long-term or will progress to kidney failure. Even patients who 
do not progress but remain nephrotic are at an increased risk for life-threatening 
Figure 3. 
Electron microscopy showing diffuse subepithelial electron dense deposits (see arrowheads) in MN.
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thromboembolic and cardiovascular events [30, 35, 36]. A rapid decline in kidney 
function should raise the possibility of a superimposed condition, such as inter-
stitial nephritis, renal vein thrombosis or acute tubular necrosis due to sepsis in an 
immunocompromised patient.
7. Predicting factors
Many individual factors, such as advanced age, male sex, degree of kid-
ney impairment on presentation, degree of chronicity in the kidney biopsy 
(e.g., degree of interstitial fibrosis, tubular atrophy, vascular damage and glo-
merulosclerosis), degree of proteinuria and anti-PLA2R antibody titre have all 
been reported to be predictors of prognosis and/or response to immunosuppres-
sive therapy in patients with MN [34, 37]. Pei et al. observed a 47% higher risk 
of kidney disease progression in patients with proteinuria exceeding 4 g/24 hour 
for longer than 18 months and a 66% higher risk in patients with proteinuria 
exceeding 8 g/24 hour for more than 6 months [38]. Similarly, PLA2R antibodies 
appear to correlate with disease activity, response to therapy and also prognosis 
[18, 34, 39, 40]. In particular, higher antibody levels are linked to a higher risk 
of declining kidney function, suggesting that these affected individuals may 
benefit from earlier initiation of immunosuppression [18]. Conversely, favour-
able outcomes have been shown in patients who are negative for anti-PLA2R 
antibodies.
8. Response measurements
The best-accepted responses are improved kidney survival and CR of protein-
uria. CR is defined as a urine protein excretion of <0.3 g/24 hour accompanied by 
a normal serum albumin concentration and normal serum creatinine [41]. Partial 
remission (PR) has been also recognised as a positive outcome and is defined as 
urine protein excretion of <3.5 g/24 hour or reduced by at least 50% from peak val-
ues accompanied by an improvement or normalisation of the serum albumin con-
centration and stable serum creatinine [41]. Approximately 30% of MN cases will 
relapse subsequent to a CR [42]. The great majority who do, however, will relapse 
to sub-nephrotic-range proteinuria and will have stable long-term function [42]. A 
review of 350 nephrotic patients with MN found that the 10-year kidney survival 
was 100% in the CR group, 90% in the PR group, and 45% in the no-remission 
group [43]. Respective rates of glomerular filtration rate decline were −0.12 ± 0.40, 
−0.17 ± 0.50 and −0.86 ± 1.08 mL/minute/month, such that the attainment of CR 
or PR independently predicted a much more favourable kidney function prognosis 
[43]. In patients who are anti-PLA2R antibody positive, reduction in circulating 
antibody titre precedes clinical remission, and furthermore, persistence of antibody 
despite treatment is associated with clinical resistance [44]. Future definitions of 
remission of this disease may well incorporate elements of both clinical and sero-
logical remission.
9. Treatment
Based on the predictive factors described above, patients can be rationally 
assigned to either conservative (non-immunosuppressive) therapy or immunosup-
pressive therapy.
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10. Conservative therapy
Conservative therapy includes controlling oedema, dietary protein intake, blood 
pressure, and hyperlipidaemia. MN patients develop significant oedema and to con-
trol the oedema, loop diuretic is the mainstay of treatment along with low-salt diet. 
High salt diet intake, apart from worsening the oedema, can also significantly impair 
the beneficial effects of renin-angiotensin blockade, which are one of the key compo-
nents of conservative therapy. A normal dietary protein intake (0.75–1.0 g/kg/day) is 
usually recommended. A recent meta-analysis including 44,989 participants showed 
more intensive blood pressure-lowering (mean blood pressure levels of 133/76 mm 
Hg, compared with 140/81 mm Hg in the less intensive treatment group) achieved a 
relative risk reduction of albuminuria by 10% [45]. Anti-proteinuric agents, such as 
angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers 
(ARBs), should be used as first-line antihypertensive agents [46, 47]. In patients with 
lower levels of proteinuria (<4 g/24 hour), treatment with an ACEi or an ARB may be 
sufficient to reduce proteinuria to sub-nephrotic levels thereby appreciably mitigating 
kidney and cardiovascular risks. However, in patients with higher degrees of protein-
uria, the use of these medications alone is unlikely to result in a substantial reduction 
in proteinuria or preservation of kidney function [48].
Statins should be prescribed to control hypercholesterolaemia and attenuate the 
heightened cardiovascular risk observed in patients with MN [49].
Patients with severe nephrotic syndrome are at increased risk of thrombo-
embolic complications. Lionaki et al. reported that clinically apparent venous 
thromboembolism occurred in 7% of patients with MN and the risk was higher 
if the serum albumin was below 2.8 g/dL [30]. In a retrospective review of MN 
patients with nephrotic range proteinuria, use of prophylactic anticoagulation has 
been shown to be associated with a reduction in fatal thromboembolic episodes 
and benefits of anticoagulation outweigh the risk of bleeding [50]. In general, MN 
patients who are severely nephrotic (proteinuria >10 g/24 hour and serum albumin 
of <2.5 g/dL) should be considered for anticoagulation [30].
11. Immunosuppressive therapy
Several treatment strategies using immunosuppressive therapy have been shown 
to be successful in reducing proteinuria in MN [51]. Based on their risk factor 
profiles, patients are grouped into low, medium and high-risk categories.
12. Treatment of low-risk patients
Patients in the low-risk group are categorised by a <5% risk of kidney disease 
progression over 5 years of observation. Patients in this group would have normal 
kidney function and proteinuria of ≤4 g/24 hours over a 6-month observation 
period. Evidence to support this approach comes from published validation studies 
[43, 52]. Such patients therefore do well with a conservative treatment approach, as 
outlined above [53].
13. Treatment of medium-risk patients
Patients in this group have preserved renal function and daily urinary protein 
excretion rates of 4–8 g/24 hours which continue unabated following a 6 month 
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period of conservative therapy. These patients warrant immunosuppressive therapy 
with one or more of the following options:
13.1 Corticosteroid monotherapy
An early collaborative randomized study of 72 adult patients with idiopathic 
nephrotic syndrome demonstrated that a 2–3 month course of high-dose alternate-
day prednisone when compared to placebo resulted in a significant reduction in 
progression to kidney failure but there was no effect on the degree of proteinuria. 
Ten of the 38 placebo-treated and one of the 34 prednisone-treated patient were 
in renal failure (creatinine more than 5 mg/dL [440 μmol/L]) or dead (p < 0.02) 
[54]. A subsequent prospective randomised study comparing a 6-month course of 
alternate day prednisone (45 mg/m2) or no specific treatment in 158 patients with 
idiopathic MN showed no significant benefit of corticosteroid treatment alone 
in either induction of remission or preservation of kidney function over a mean 
follow-up period of 48 months [55]. Hence, corticosteroid monotherapy have been 
shown to be ineffective inducing remission in patients with MN.
13.2 Cytotoxic agents combined with corticosteroids
A number of randomised trials have suggested that alternating monthly regimen 
of steroids and cytotoxic agents is more likely to induce CR of nephrotic syndrome, 
and halt disease progression compared to no therapy or corticosteroids alone. The 
first study by Ponticelli’s group compared the effects of corticosteroids alternat-
ing monthly with chlorambucil to conservative treatment in 67 adult patients 
with MN [56]. The regimen was given over a 6-month period. It consists of 1 g of 
intravenous methylprednisolone (MTP)/day for first 3 days of months 1, 3 and 5 
followed by 27 days of oral methylprednisolone 0.5 mg/kg/day for the remainder of 
the month. In the alternating months (months 2, 4 and 6), chlorambucil 0.2 mg/
kg/day is used instead of corticosteroids. Compared with controls, patients in the 
intervention group experienced higher rates of CR or PR (72 vs. 30%, p = 0.001) 
and significantly better preserved kidney function at 1 year (p = 0.011) and 2 years 
(p < 0.0001). After 10 years of follow-up, patients treated with combination 
therapy had a 92% probability of kidney survival compared with 60% in the control 
group (p = 0.004), and the probability of achieving a CR or PR was 83% in the 
treatment group, and only 38% in the controls (p = 0.000) [57]. A second study 
by the same group, compared the original chlorambucil regimen (45 patients) as 
described above to MTP pulses plus steroid alone for 6 months (47 patients) [58]. 
Compared to the steroids alone regimen, treatment with the chlorambucil regimen 
resulted in higher proportions of patients without nephrotic syndrome at 3 years 
(66 vs. 40%, p = 0.011), although the result was no longer statistically significant 
by 4 years (62 vs. 42%, p = 0.102) chlorambucil-treated patients also had longer 
mean ratios of months in remission (0.52 vs. 0.31, p = 0.008) [58]. In a third study 
from the same investigators, patients were enrolled in a 6-month study comparing 
corticosteroids (1 gm of intravenous MTP day for first 3 days of months 1, 3 and 5 
followed by 27 days of oral methylprednisolone 0.5 mg/kg/day for the remainder 
of the month) alternating monthly with either chlorambucil (0.2 mg/kg/day) or 
oral cyclophosphamide (2.5 mg/kg/day) in months 2, 4 and 6 [59]. No significant 
differences were observed between the two groups with respect to remission rate 
(CR or PR) at 1 year (82 vs. 93%, respectively, p = 0.116), subsequent relapse rate 
(31 vs. 25%, or changes in proteinuria or reciprocal serum creatinine over time.
In an open-label, parallel-arm, randomised controlled trial, Jha and colleagues 
compared the effects of alternating monthly prednisolone and cyclophosphamide 
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for 6 months versus conservative treatment (salt restriction, blood pressure con-
trol and diuretic therapy) on remission, kidney disease progression and quality 
of life in adult patients with MN and nephrotic syndrome [60]. Compared with 
controls, those who received cyclophosphamide and steroids were more likely to 
achieve remission (72 vs. 35%, p < 0.001) and have better kidney survival, defined 
as not experiencing doubling of serum creatinine, dialysis or death (79 vs. 44%, 
p = 0.0006) [60]. They also had higher mean quality of life scores at 10 years, as 
measured by a visual analogue scale (7.31 ± 0.76 vs. 6.61 ± 1.08, p < 0.01). Infectious 
complications were similar between the groups.
Adverse effects associated with these agents, particularly infertility and malig-
nancy, are the major drawbacks of cytotoxics combined with corticosteroids. The 
risk of malignancy is not increased for patients treated with cumulative cyclophos-
phamide doses of up to 36 g but increases significantly thereafter [61].
13.3 Cyclosporine
Early uncontrolled studies of cyclosporine (CSA) suggested an initial benefit 
but a high relapse rate [62, 63]. In the first single-blind randomised controlled 
study, 51 patients with steroid-resistant MN were treated with low-dose prednisone 
(0.15 mg/kg/day up to a maximum dose of 15 mg and reduced after 26 weeks by 
thirds at 4-week intervals) plus CsA (3.5 mg/kg/day in two divided doses and 
aiming for a trough level between 125 and 225 μg/L) and compared to patients 
treated with placebo plus prednisone (similar dose to treatment arm) [64]. At the 
end of 26 weeks of treatment, 75% of patients (21 of 28) in the CsA group versus 
only 22% of patients (5 of 23) in the controls had achieved a CR or PR (P < 0.001). 
Relapses occurred in about 40% of patients within 1 year of discontinuation of CsA 
treatment. In an observational study of 36 adults with idiopathic MN and steroid-
dependent or -resistant nephrotic syndrome treated with CsA (5.54 ± 0.81 mg/kg/
day), the German Cyclosporine in Nephrotic Syndrome Study Group reported that 
prolonging CsA treatment (>1 year) resulted in a higher (34% CR at 1 year) and 
more sustained rate of remission [65]. Prolonged low-dose CsA (~1.5 mg/kg/day) 
could be considered for long-term maintenance of patients who achieve CR or PR, 
especially in patients at high risk of relapse [66]. However, this needs to be weighed 
against the risk of renal scarring from long-term exposure to CsA.
13.4 Tacrolimus
Tacrolimus is also a reasonable consideration for the treatment of MN. In an 
open-label, randomised controlled trial of tacrolimus versus conservative therapy 
in 48 patients with MN, normal kidney function and nephrotic syndrome from 13 
Spanish centres, Praga et al. demonstrated that tacrolimus monotherapy resulted in 
a higher probability of remission (CR or PR) at 12 months (76 vs. 22%, p < 0.001) 
with shorter mean time to remission (61. vs. 11.3 months, p = 0.003) [67]. In 
patients with CR or PR at 18 months who subsequently had their tacrolimus with-
drawn, 47% of patients experienced a relapse of nephrotic syndrome within a mean 
period of 4.2 months.
14. Treatment of high-risk patients
This group of patients is characterised by worsening kidney failure, extremely 
high anti-PLA2R antibodies or persistent high proteinuria (≥8 g/day).
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14.1 Corticosteroids
A prospective double-blind randomised controlled trial by the UK Medical 
Research assessed the medium-term effect of an 8-week course of high-dose 
prednisolone (100–150 mg on alternate day) in a high risk MN population [68]. A 
total of 103 patients with preserved kidney function (average creatinine clearance 
88 ± 30 mL/minute) were randomised to the treatment group (n = 52) or to the 
control group (n = 51). At 36 months, there was no significant difference regarding 
the degree of proteinuria or loss of kidney function between the control and the 
treatment group.
14.2 Cytotoxic agents combined with corticosteroids
Another randomised controlled trial by the same group assessed whether 
immunosuppression preserved kidney function in patients with idiopathic MN 
and declining kidney function [69]. The study randomised patients to either 
combination of prednisolone and chlorambucil (intravenous methyl prednisolone 
1 g per day for 3 consecutive days then oral prednisolone 0·5 mg/kg per day for 
28 days during months 1, 3, and 5. During months 2, 4, and 6, patients received oral 
chlorambucil at a starting dose of 0·15 mg/kg per day) (n = 33) or CsA (12 months 
of CsA received a starting dose of 5 mg/kg per day, aiming for trough level of 
100–200 μg/L) (n = 37) or supportive therapy alone (n = 38). The primary endpoint 
was a further 20% decline in Cockcroft-Gault estimated creatinine clearance and 
occurred less frequently in the prednisolone and chlorambucil group than in either 
the cyclosporin or supportive therapy groups (58 vs. 81 vs. 84%, respectively, 
p = 0.003). Serious adverse events were also most common in the prednisolone and 
chlorambucil group (52 vs. 46 vs. 29%, respectively).
14.3 Cyclosporine
So far, there has been only one controlled trial with CsA in patients with high-
grade proteinuria and progressive kidney failure. In this study, patients with high 
risk features were randomly assigned to either CsA (3.5 mg/kg/day taken in two 
divided doses, and aiming for trough level between 110 and 170 μg/L) treatment 
(nine patients) or placebo (eight patients) for 12 months) [70]. The average creati-
nine clearance of these patients was 51 mL/minute/1.73 m2 and they had an average 
daily urine protein excretion of 11.5 g/day. After 12 months, there was a significant 
improvement in renal function as measured by the change in slopes, being greater 
in the CsA versus placebo patients [70 vs. 7% improvement, mean difference 1.5 
(95% CI 0.2–3.1)]. Proteinuria in the CsA group was reduced by an average of  
4.5 g/day, where in the placebo group there was an increase of 0.7 g/day by month 3 
(p = 0.02).
14.4 Mycophenolate mofetil
In a pilot study, Miller et al. treated 16 medium or high risk MN patients with 
1.5–2 g/day of mycophenolate mofetil for a mean period of 8 months [71]. There 
were no significant changes in mean serum creatinine or albumin levels over the 
course of the study. Similar results were reported in a retrospective analysis of 
17 patients with MN [72], in which treatment with mycophenolate mofetil for 
12 months combined with steroids resulted in a 61% reduction of proteinuria. 
Kidney function improved in three of six patients with kidney failure.
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Branten et al. reported 32 patients with MN and kidney insufficiency treated 
with mycophenolate mofetil (1 g twice a day) plus steroids (IV MTP 1 g for 3 con-
secutive days at the beginning of months 1, 3, and 5 and oral prednisone, 0.5 mg/kg 
every other day, for 6 months with subsequent tapering for 12 months) and com-
pared the results with those obtained for 32 patients from a historic control group 
treated for the same period of time with oral cyclophosphamide (1.5 mg/kg/day) 
and steroids (similar steroid schedule to above) [73]. Overall, 21 mycophenolate-
treated patients developed PR of proteinuria, six patients experienced at least 
50% reduction in proteinuria, and five patients experienced no response. No 
significant differences were observed between the intervention and control groups 
at 12 months with respect to the occurrence of CR or PR (66 vs. 72%, respectively, 
p = 0.30) or adverse drug reactions (75 vs. 69%, p = 0.60), although relapse 
occurred more frequently in those who received mycophenolate mofetil  
(38 vs. 13%, p < 0.01).
14.5 Rituximab
In a pilot study of eight MN patients treated with four weekly courses of 
rituximab (375 mg/m2), two achieved CR and three achieved PR by 12 months 
[74, 75]. Mean 24-hour urinary protein excretion rates fell by 66% from 8.6 to 3.0 g 
(p < 0.005). Kidney function remained stable in all patients. Adverse effects were 
reported as mild and included chills, fever and an anxiety reaction.
In another prospective open-label pilot trial, 15 patients with idiopathic MN 
and proteinuria of >4 g/24 hour despite conservative therapy for >3 months 
received two doses of rituximab (1 g) 2 weeks apart [76]. At 6 months, another 
two fortnightly doses of rituximab were administered to patients with measured 
24-hour urinary protein excretion rates exceeding 3 g and total CD19+ B-cell 
counts exceeding 15 cells/μL. Mean proteinuria levels decreased by 54% from 
13.0 g/24 hour at baseline to 6.0 g/24 hour at 12 months. At 12 months, two 
patients achieved CR, six achieved PR, five did not respond and two progressed to 
ESKD. Rituximab was well-tolerated and was effective in reducing proteinuria in 
patients with idiopathic MN.
The Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy 
(GEMRITUX) study was a French multicentre, randomised, controlled trial which 
evaluated the efficacy of rituximab in inducing remission in medium- to high-risk 
patients with idiopathic membranous nephropathy [77]. Thirty-seven patients 
received both rituximab (375 mg/m2 on days 1 and 8) and conservative therapy 
and 38 patients received conservative therapy alone. There was no significant 
difference in remission rates at 6 months (35.1% in rituximab group compared to 
21.1% in conservative group, p = 0.21). However, with extended follow up (median 
17.0 months), remission rates were significantly higher in the rituximab group 
(64.9 vs. 34.2%, p < 0.01).
The Membranous Nephropathy Trial Of Rituximab (MENTOR) study 
(NCT01180036) was a multicentre, randomised controlled trial comparing the effi-
cacy and safety of rituximab to CsA in medium to high-risk patients with idiopathic 
MN [78]. Patients with proteinuria ≥5 g/24 hour following a minimum period of 
3 months of conservative non-immunosuppressive therapy were randomised to 
receive IV rituximab 1000 mg (day 1 and 15, then repeated at 6 months) or oral 
CsA (3.5 mg/kg/day for 12 months). Patients who received CsA had a higher rate of 
treatment failure at 24 months compared with those who received rituximab  
(79.4 vs. 37.5%), and CR or PR occurred in 62.5% of the rituximab cohort compared 
with 20.6% of those who received CsA (odds ratio 6.0, 95% CI 2.7–13.2, P < 0.0001).
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Numerous prospective uncontrolled studies have been performed evaluating the 
efficacy of rituximab in idiopathic MN and are summarised in Table 1 [75, 77–87].
14.6 Eculizumab
Eculizumab is a humanised anti-C5 monoclonal antibody designed to prevent 
the cleavage of C5 into its proinflammatory by-products. In a randomised placebo-
controlled trial in 200 patients with MN, eculizumab, although well-tolerated, 
failed to show any significant reduction of proteinuria. There were concerns that 
the dosing schedules were inadequate as inhibition of complement was not uni-
formly demonstrated. Patients in the eculizumab arm were treated every 2 weeks 
with two different intravenous dose regimens over a total of 16 weeks [88]. Neither 
of the active drug regimens of eculizumab showed any significant effect on pro-
teinuria or kidney function compared to placebo. More encouraging results were 
seen in a continuation of the original study, in which eculizumab was used for up 
to 1 year, with a significant reduction in proteinuria in some patients (including 
two patients who went into CR). More long-term studies need to be performed 
with anti-C5 monoclonal antibody to determine its role in the treatment of MN.
14.7 Adrenocorticotropic hormone
In a study by Berg and colleagues, synthetic adrenocorticotropic hormone 
(ACTH) administered 1 mg twice per week for 1 year decreased proteinuria in 
patients with idiopathic MN [89, 90]. Ponticelli et al. conducted a randomised 
pilot study comparing methylprednisolone plus a cytotoxic agent versus syn-
thetic ACTH in 32 patients with idiopathic MN [91]. In this study, 16 patients 
were randomly assigned to receive three cycles of MTP (IV MTP 1 g, adminis-
tered for 3 consecutive days, and then 0.4 mg/kg body weight per day for 27 days, 
administered orally) and each cycle was followed by 1 month of treatment with 
either chlorambucil (0.2 mg/kg/day orally) or cyclophosphamide (2.5 mg/kg/
day orally), and 16 were assigned to receive ACTH 1 mg intramuscular injections 
administered initially one injection every other week to two injections per week 
for a total treatment period of 1 year. No significant differences were observed in 
remission rates between the ACTH and control groups (87 vs. 93%, respectively), 
Medication discontinuation rates due to lack of efficacy or adverse drug reactions 
were 12.5% in both groups. A pilot study by Hladunewich et al. administered 20 
idiopathic MN patients with either 40 or 80 IU twice-weekly dose of Acthar® 
gel and found a significant improvement in proteinuria at 12 months in the entire 
cohort [92]. There was >50% decrease in proteinuria in 65% of patients and 
no significant adverse effects were documented. Improvement in serum anti-
PLA2R antibodies was not noted in all patients. Measured anti-PLA2R antibodies 
became undetectable in three out of 15 patients and appreciably declined in 
another four patients.
A suggested, risk-based treatment algorithm is displayed in Figure 4. It is 
intended as a guide only and should additionally take into account individual 
patient circumstances and preferences. Patients who do not respond well or relapse 
after a first course of immunosuppression therapy may benefit from a second 
course of immunosuppression.
Patients with severe kidney insufficiency (serum creatinine of ≥3.5 mg/dL or 
309 μmol/L) are less likely to benefit from immunosuppression therapy and more 
likely to experience treatment-related harm, such that consideration should be given 
to conservative therapy only and plans made for transplantation in the future [41].
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Author/year Level of 
evidence
Risk 
group
N Treatment regimens Median 
follow-up 
(months)
Outcomes/comments
Dahan/2017 [77] RCT Medium-
high
75 RTX 375 mg/m2 on day 1 and 8 + NIAT vs. NIAT alone 17 At 6 months, 13 of 37 (35.1%) treated with 
RTX + NIAT achieved remission vs. 8 of 38 
(21.1%) controls (p = 0.21). Significantly 
higher rates of PLA2R antibody depletion at 3 
and 6 months in RTX + NIAT group.
Fiorentino/2016 
[79]
Prospective 
uncontrolled
Medium-
high
38 RTX 375 mg/m2 monthly × 6 15 29 of 38 (76.3%) achieved remission −15 
(39.5%) CR and 14 (36.8%) PR. Proteinuria 
significantly reduced. Kidney function 
stable. No significant adverse events.
Bagchi/2018 [80] Retrospective 
uncontrolled
High 21 RTX 500 mg × 2 doses 7–10 days apart ± 3rd dose after 
4–6 weeks if CD19 not depleted
13 13 of 21 (61.9%) achieved remission −4 
(19.05) CR and 9 (42.9%) PR. One patient 
relapsed after achieving PR. Kidney survival 
was significantly better in responders (p 
−0.0037).
Moroni [81] Prospective 
uncontrolled
Medium-
high
34 RTX 375 mg/m2 × 1 dose (n = 18) or ×2 2 weeks apart 
(n = 16)
23.9 (mean) At 12 months, 5 (14.7%) CR, 10 (29.4%) PR 
and 19 (55.8%) no response. Outcome similar 
for one vs. two doses.
Waldman/2016 
[82]
Prospective High 13 CsA 3 mg/kg/day for 6 months then tapered by 50 mg/
day every 3 weeks plus RTX 1000 mg day 1 and 15, then 
after 6 months when CD19+ B cell count ≥5 cells/μL.
41 (mean) By 6 months 85% achieved remission 
(CR + PR). By 12 months, 54% achieved CR. 
2 relapsed by 24 months. Treatment well 
tolerated.
Ruggenenti/2015 
[83]
Prospective High 132 RTX 375 mg/m2 weekly ×4 30.8 84 of 132 (63.6%) achieved remission 
(CR + PR), 43 (32.6%) achieved CR. Anti-
PLA2R antibody depletion preceded 
remission.
Ruggenenti/2003 
[75]
Prospective Medium 8 RTX 375 mg/m2 weekly ×4 Not 
specified
Significant reduction in proteinuria. Kidney 
function stabilised. two achieved CR and 
three achieved PR.
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evidence
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Outcomes/comments
Ruggenenti/2012 
[84]
Prospective High 100 RTX 375 mg/m2 weekly ×4 29 (median) At end of follow up, 65% achieved CR or 
PR. Median time to remission 7.1 months. 
Kidney function improved in those who 
achieved CR.
Fervenza/2010 
[85]
Prospective Medium 20 RTX 375 mg/m2 weekly ×4, repeated at 6 months Not 
specified
Proteinuria reduced from 11.9 g/24 hours to 
4.2 and 2.0 g/24 hours at 12 and 24 months, 
respectively. At 24 months, 4 of 18 achieved 
CR, 12 of 18 achieved PR and 1 relapsed. 
Remission rates higher than fortnightly 
dosing.
Fervenza/2008 
[86]
Prospective High 14 RTX 1000 mg on day 1 and 15, repeated at 6 months if 
proteinuria >3 g/24 hours and CD9 + B cell >15 cells/μL
12 At 6 months, four achieved PR. At 
12 months, two achieved CR and 6 PR.
Fervenza/2015 
[78]
Results from 
abstract
RCT High 130 RTX 1000 mg on day 1 and 15, repeated at 6 months vs. 
CsA 3.5–5 mg/kg/day for 6 months
24 At 24 months, CR or PR in RTX arm was 62.5 
vs. 20.6% in the CsA arm
Treatment failure higher in CsA group 
compared to RTX group (79.4 vs. 37.5%).
Rojas-
Rivera/2015 [87]
RCT High MTP 1 g IV day 1–3 then MTP PO 0.5 mg/kg/day for 
day 4–30 on months 1, 3 and 5 and cyclophosphamide 
PO 2.0 mg/kg/day for 30 days on months 2, 4 and 6 vs. 
tacrolimus 0.05 mg/kg/day for 6 months, then tapered 
to withdrawal by 9 months + RTX 1 g at day 180.
Results awaited
Abbreviations are: RCT, randomised controlled trial; RTX, rituximab; NIAT, non-immunosuppressive antiproteinuric therapy; CsA, cyclosporine; CR, CR; PR, partial remission; MTP, methylprednisolone; 
PO, per oral.
Table 1. 
Rituximab treatment of idiopathic MN.
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15. Conclusion
In conclusion, controlling proteinuria (either CR or PR) in MN is clearly associ-
ated with a slower rate of kidney disease progression. Newer biomarkers, such 
anti-PLA2R antibody and THSD7A, are showing some promising role in differentiat-
ing between primary versus secondary MN, predicting prognosis and response to 
therapy. There are no standard or universal first-line specific therapeutic options for 
idiopathic MN. Supportive or conservative care, including dietary salt restriction, 
anti-proteinuric therapy with ACEi or ARB, optimisation of blood pressure and 
serum cholesterol, and management of cardiovascular and thromboembolic risks, 
should be given in all cases. Immunosuppressive therapy, such as cytotoxic agents and 
steroids, calcineurin inhibitors and steroids, rituximab (with or without calcineurin 
inhibitors), and ACTH, should be considered in patients at medium or high risk of 
kidney disease progression, cardiovascular disease or thromboembolic complications, 
as evidenced by heavy proteinuria (>4 g/day) and/or deteriorating kidney function.
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Figure 4. 
Treatment algorithm for idiopathic MN. Based on the renal function and degree of proteinuria at presentation, 
patients with MN can be classified in to low, medium and high risk category for progression. Patients in the low risk 
category should be managed with conservative therapy alone but during follow up if they transform in to medium or 
high risk category then they should be considered for immunosuppressive therapy. Patients in the medium risk category 
should be treated with conservative therapy for at least 6 months and despite that if they still have more than 4 g/
day of proteinuria then they should be considered for immunosuppressive therapy. Patients in the high risk category 
shouldn’t wait for 6 months before starting immunosuppressive therapy. Patients in the medium or high risk category 
could be treated with either cytotoxics plus corticosteroids or CNI plus corticosteroids or rituximab with or without 
CNI. If there is no response to one agent, consider alternate agent. If the patient is refractory to all three agents, then 
they could be treated either with MMF or ACTH. ⋆Conservative treatment involves the use of ACEi ± ARB blocker 
to maintain BP < 125/75 mmHg, lipid control with HMG-CoA reductase inhibitor, dietary protein restriction 
(0.6–0.8 g/kg ideal body weight/day), dietary NaCl intake (goal is 2–3 g Na) to optimise antiproteinuric effects 
of ACEi and ARBs, smoking cessation, and attempt to reduce obesity, if present. Abbreviations are: anti-PLA2R, 
phospholipase A2 receptor antibody; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor 
blocker; CNI, calcineurin inhibitor; ACTH, adrenocorticotrophic hormone; MMF, mycophenolate mofetil.
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